Hormone Therapy + Medications for Prostate Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as much as possible, which might reduce the chances of the cancer coming back in the future. These treatments include a hormone injection given monthly or every three months and the study drugs, which include abiraterone acetate, prednisone, and apalutamide. These medications are being used in combination with surgery and maybe radiotherapy because studies have shown that any single approach on its own is not sufficient to control or get rid of the cancer especially if they have high risk or aggressive features. The researchers hope to learn if combining the study drugs with surgery and radiation will get rid of the cancer from participants' prostates and reduce their prostate-specific antigen (PSA) to an undetectable level.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, it mentions that certain medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks before starting the treatment. It's best to discuss your current medications with the trial team to ensure compatibility.
What data supports the effectiveness of GnRH antagonists in the treatment of prostate cancer?
Research shows that GnRH antagonists are effective in rapidly reducing testosterone levels, which helps in managing prostate cancer. They are at least as effective as GnRH agonists in terms of controlling cancer progression and are particularly beneficial for patients with cardiovascular issues.12345
Is hormone therapy for prostate cancer safe for the heart?
How is the hormone therapy with GnRH agonist/antagonist and radical prostatectomy unique for prostate cancer?
This treatment combines hormone therapy with GnRH agonists or antagonists, which rapidly reduce testosterone levels, with radical prostatectomy, a surgical procedure to remove the prostate. The unique aspect is the combination of rapid testosterone suppression with surgery, potentially offering better cancer control for high-risk prostate cancer patients.125810
Research Team
Matthew Dallos, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Men over 18 with advanced prostate cancer, who can consent and have adequate organ function. They must not have other active cancers or major health issues that could interfere with the trial, no prior treatments for prostate cancer (with some exceptions), and agree to use effective contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Hormone Treatment
Participants receive hormone injections and study drugs (abiraterone acetate, prednisone, and apalutamide) to reduce male hormone levels before surgery
Surgery
Participants undergo surgery to remove prostate cancer
Radiation
Participants may receive radiotherapy to further treat prostate cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment, including PSA levels
Treatment Details
Interventions
- Abiraterone Acetate
- Apalutamide
- Extended Pelvic lymphadenectomy
- GnRH agonist/antagonist
- Prednisone
- Radical Prostatectomy
- Stereotactic Body Radiation Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Dana-Farber Cancer Institute
Collaborator